Royal Bank of Canada Increases Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $175.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target lifted by stock analysts at Royal Bank of Canada from $174.00 to $175.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank of Canada’s price target points to a potential upside of 59.99% from the company’s current price.

JAZZ has been the topic of a number of other reports. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Morgan Stanley lowered their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Needham & Company LLC restated a “buy” rating and issued a $205.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. UBS Group lowered their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research report on Tuesday, July 2nd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $173.14.

Jazz Pharmaceuticals Trading Up 0.8 %

JAZZ stock opened at $109.38 on Friday. The company has a market capitalization of $6.90 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 1.36 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $137.38. The business has a 50 day simple moving average of $111.02 and a two-hundred day simple moving average of $110.39.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. Research analysts anticipate that Jazz Pharmaceuticals will post 16.03 EPS for the current fiscal year.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. EverSource Wealth Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Jazz Pharmaceuticals by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock worth $1,937,000 after purchasing an additional 99 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 1.4% during the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after purchasing an additional 105 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in shares of Jazz Pharmaceuticals by 1.1% during the 1st quarter. Pinnacle Associates Ltd. now owns 10,371 shares of the specialty pharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 110 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.